TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1430299

Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 250 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 500 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 1000 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral cefprozil 500 mg
Number of subjects: 24
Study: 2864374

Group type: EXPERIMENTAL
Intervention: Beta-blocker (oxprenolol) treatment
Number of subjects: 6357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6357
Study: 31888728

Group type: EXPERIMENTAL
Intervention: Yishen Tongbi decoction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 100
Study: 28871506

Group type: EXPERIMENTAL
Intervention: Project RISE intervention
Number of subjects: 165
Study: 27664491

Group type: EXPERIMENTAL
Intervention: 500 mg/day resveratrol capsules
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24723209

Group type: EXPERIMENTAL
Intervention: Formalin-fixed paraffin-embedded (FFPE) tonsil tissue specimens
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Homogenised fresh-frozen tonsil tissue
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Overall assessment of HPV infection
Number of subjects: 4095
Study: 22124524

Group type: EXPERIMENTAL
Intervention: REHIT intervention (3 sessions per week for 6 weeks, low-intensity cycling with brief sprints)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: REHIT intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (maintained normal sedentary lifestyle)
Number of subjects: 29
Study: 20555273

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (sodium chloride; NaCl)
Number of subjects: 8
Study: 18084172

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (treadmill walking, thrice a week for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 60
Study: 16282517

Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 144
Study: 11898803

Group type: EXPERIMENTAL
Intervention: 70 degrees angled telescope
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0 degrees telescope
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 and 45 degrees telescopes
Number of subjects: 10
Study: 10536125

Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg once daily)
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg twice daily)
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1559

Group type: EXPERIMENTAL
Intervention: Oseltamivir (combined groups)
Number of subjects: 1559
Study: 8808537

Group type: EXPERIMENTAL
Intervention: Ankle taping
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untaped (control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Athletic footwear (untaped)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Athletic footwear (taped)
Number of subjects: 24
Study: 2252170

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol and alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhalation anaesthesia with nitrous oxide and enflurane at 1.3 MAC
Number of subjects: 40
Study: 7027059

Group type: EXPERIMENTAL
Intervention: Protocol 0171 (VCR, PRED, MTX, cyclophosphamide +/‐ +/‐ 6‐MP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Regimen 'A' (without 6‐MP in intensification)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Regimen 'B' (with 6‐MP in intensification)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Protocol 0276/A
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Best regimen
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Relapses
Number of subjects: 38
Study: 31521525

Group type: EXPERIMENTAL
Intervention: Medicaid insurance
Number of subjects: 96

Group type: COMPARATOR
Intervention: Blue Cross Blue Shield (BCBS) private insurance
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Medicaid insurance in expanded states
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Medicaid insurance in unexpanded states
Number of subjects: 96
Study: 30507375

Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 26871245

Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up for 3 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no education and telephone follow-up)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up
Number of subjects: 88
Study: 25483647

Group type: EXPERIMENTAL
Intervention: Bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (± 15 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tetravalent blend of CYD-1;3;4 and VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reference CYD-TDV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Japanese encephalitis (JE) vaccine followed by CYD-TDV
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tetravalent CYD vaccine (CYD-TDV)
Number of subjects: 150
Study: 22006544

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 19236546

Group type: EXPERIMENTAL
Intervention: Combizym treatment (2 weeks, two tablets post-meal, t.i.d.)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo treatment (2 weeks, two tablets post-meal, t.i.d.)
Number of subjects: 151
Study: 17999733

Group type: EXPERIMENTAL
Intervention: Specific paste for complete dentures (Corega Brite)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neutral soap
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 45
Study: 15470286

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (irbesartan, olmesartan medoxomil, telmisartan, valsartan) in combination with hydrochlorothiazide (40 mg/25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers with hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy with either angiotensin II receptor blockers or hydrochlorothiazide
Number of subjects: 0
Study: 11828263

Group type: EXPERIMENTAL
Intervention: Standard dose dacarbazine (arm A)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: High-dose dacarbazine (arm B)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Aggressive regimen without dacarbazine (arm C)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Non-aggressive regimen without dacarbazine (arm D)
Number of subjects: 219
Study: 10078673

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine-4 microg fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine-2 microg fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.05% ropivacaine-1 microg fentanyl
Number of subjects: 30
Study: 7747374

Group type: EXPERIMENTAL
Intervention: UroLume endourethral prosthesis
Number of subjects: 175
Study: 2105243

Group type: EXPERIMENTAL
Intervention: hMG + GH (24 IU on alternate days, total dose 144 IU)
Number of subjects: 16

Group type: COMPARATOR
Intervention: hMG + placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: hMG + GH
Number of subjects: 16
Study: 548209

Group type: EXPERIMENTAL
Intervention: Lecithin administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study: 31708453

Group type: EXPERIMENTAL
Intervention: Semi-structured telephone interviews
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Research priorities identified by participants
Number of subjects: 12
Study: 31182060

Group type: EXPERIMENTAL
Intervention: Running therapy (exercise planned two times a week for 6 months)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Running therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 46
Study: 28063226

Group type: EXPERIMENTAL
Intervention: Smartcare with financial incentives
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Smartcare
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 105
Study: 25637146

Group type: EXPERIMENTAL
Intervention: Chinese massage combined with core stability exercises
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chinese massage alone
Number of subjects: 92
Study: 23657159

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 21836137

Group type: EXPERIMENTAL
Intervention: Continuous control of tracheal cuff pressure using a pneumatic device
Number of subjects: 122

Group type: COMPARATOR
Intervention: Routine care of tracheal cuff pressure
Number of subjects: 122
Study: 18703258

Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) multimedia on vital signs with animation and audio features, used in conjunction with traditional lecture or lecture-demonstration.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group using traditional lecture or lecture-demonstration without CAL.
Number of subjects: 0
Study: 16774872

Group type: EXPERIMENTAL
Intervention: Charcoal (CC) filter tipped cigarettes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cellulose acetate (CA) filter tipped cigarettes
Number of subjects: 39
Study: 10830450

Group type: EXPERIMENTAL
Intervention: Intervention children (dietary fat modification counseling)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control children (no dietary fat modification counseling)
Number of subjects: 200
Study: 8901078

Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release (CR) oxycodone tablet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20 mg immediate-release (IR) oxycodone solution
Number of subjects: 22
Study: 1670668

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) in cerebrospinal fluid
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for cerebrospinal fluid antibodies
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (14 pyogenic meningitis, 3 aseptic meningitis, 34 other neurological disorders)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Antibody ELISA in controls
Number of subjects: 41
Study: 6666226

Group type: EXPERIMENTAL
Intervention: 60 mg ISDN (acute treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 X 60 mg ISDN (4 weeks treatment)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29401495

Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Deferred radiotherapy (control)
Number of subjects: 203
Study: 27345284

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 744 mg (delivering 400 mg isavuconazole)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (oral administration)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 372 mg (delivering 200 mg isavuconazole) with esomeprazole 40 mg/day
Number of subjects: 64
Study: 24594863

Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 22648731

Group type: EXPERIMENTAL
Intervention: 4 g per day of cis9,trans11 CLA‐enriched oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo oil (palm oil and soybean oil)
Number of subjects: 40
Study: 20079786

Group type: EXPERIMENTAL
Intervention: L-theanine (97 mg) and caffeine (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17639029

Group type: EXPERIMENTAL
Intervention: Linezolid (single and multiple dosing)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Model comparison
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Simulations of linezolid concentration-time profiles
Number of subjects: 34
Study: 16343096

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) administration after metformin treatment (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) administration after laparoscopic ovarian drilling (LOD) (group B)
Number of subjects: 28
Study: 12410501

Group type: EXPERIMENTAL
Intervention: Suture-mediated closure device (SMC); n = 96
Number of subjects: 193

Group type: COMPARATOR
Intervention: Manual compression (MC); n = 97
Number of subjects: 193
Study: 10051054

Group type: EXPERIMENTAL
Intervention: Neural network (NN) combined with genetic algorithm (GA) for predicting tacrolimus blood levels
Number of subjects: 32

Group type: COMPARATOR
Intervention: Observed tacrolimus blood levels
Number of subjects: 32
Study: 7796303

Group type: EXPERIMENTAL
Intervention: Recognition test without specific instructions on encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific encoding instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test conditions without specific encoding instructions (Experiment 2B)
Number of subjects: 0
Study: 31829793

Group type: EXPERIMENTAL
Intervention: Coffee cherry extract (CCE)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31574228

Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 0
Study: 27304977

Group type: COMPARATOR
Intervention: No enema
Number of subjects: 333

Group type: COMPARATOR
Intervention: Sodium chloride enema
Number of subjects: 333

Group type: COMPARATOR
Intervention: Soap-suds enema (SSE)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: No bowel preparation
Number of subjects: 333

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 333
Study: 26152410

Group type: EXPERIMENTAL
Intervention: Imidacloprid 10 % (w/w) / Flumethrin 4.5 % (w/w) collar (Seresto)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral afoxolaner chewable (NexGard) (dosage 3.1 - 6.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 0
Study: 22727976

Group type: EXPERIMENTAL
Intervention: Nebivolol 5mg daily (n=27)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 45
Study: 20943711

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combined therapy (Pharmacotherapy + Physiotherapy)
Number of subjects: 46
Study: 19649309

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 to 300 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lisinopril (10 to 20 mg/day)
Number of subjects: 15
Study: 17609874

Group type: EXPERIMENTAL
Intervention: HDR-BT (18 Gy, 9 Gy on days 1 + 8) plus 50.4 Gy of EBRT in group B (applicators in both prostate and SV)
Number of subjects: 41

Group type: COMPARATOR
Intervention: HDR-BT (18 Gy, 9 Gy on days 1 + 8) plus 50.4 Gy of EBRT in group A (applicators in prostate only)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Group A (prostate only)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group B (prostate and SV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 15200753

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 10/650 mg (single dose)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (multidose regimen)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 271

Group type: COMPARATOR
Intervention: Active treatment (Rofecoxib or Oxycodone/acetaminophen)
Number of subjects: 271
Study: 11506104

Group type: EXPERIMENTAL
Intervention: Model-training group (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Didactic-teaching group (n = 12)
Number of subjects: 24
Study: 9601649

Group type: EXPERIMENTAL
Intervention: In situ end-labelling (ISEL) for detecting apoptotic cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for PARP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry for Ku80
Number of subjects: 0
Study: 7721516

Group type: EXPERIMENTAL
Intervention: High level of physical activity
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Moderate level of physical activity
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Low level of physical activity
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Physical activity
Number of subjects: 1206
Study: 2915410

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl citrate (75 micrograms/h)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl citrate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1069608

Group type: COMPARATOR
Intervention: Daunorubicin alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine
Number of subjects: 66
Study: 31221165

Group type: EXPERIMENTAL
Intervention: Multi-arm trial designs with varying antibiotic treatment durations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional head-to-head comparisons of limited numbers of durations
Number of subjects: 0
Study: 28094141

Group type: EXPERIMENTAL
Intervention: 300 mg intravenous zanamivir
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: 600 mg intravenous zanamivir
Number of subjects: 626

Group type: COMPARATOR
Intervention: Oseltamivir (75 mg oral, twice a day)
Number of subjects: 626
Study: 25108573

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (enhanced dietary energy and protein)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 165
Study: 23893223

Group type: EXPERIMENTAL
Intervention: Lifestyle modification coaching program (8-week telecoaching session following face-to-face education)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lifestyle modification coaching program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (face-to-face education only)
Number of subjects: 61
Study: 21525686

Group type: EXPERIMENTAL
Intervention: 2 ml of 2% lidocaine HCl with 1:80,000 epinephrine injected into the buccal vestibule
Number of subjects: 75

Group type: COMPARATOR
Intervention: Palatal injection
Number of subjects: 75
Study: 18053047

Group type: EXPERIMENTAL
Intervention: 1,550‐nm diode‐pumped erbium fiber laser (Fraxel SR, Reliant Technologies)
Number of subjects: 10
Study: 16529799

Group type: EXPERIMENTAL
Intervention: Experimental stress (Trier Social Stress Test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-stress procedure
Number of subjects: 32
Study: 12972684

Group type: EXPERIMENTAL
Intervention: Diet plus aerobic dance (DA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diet plus walking (DW)
Number of subjects: 90
Study: 11105340

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 205
Study: 9101374

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.05 mg/day 17 beta‐estradiol) and calcium
Number of subjects: 90

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen in high bone turnover (HT) patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen in low bone turnover (LT) patients
Number of subjects: 90
Study: 1529687

Group type: EXPERIMENTAL
Intervention: Insulin‐like Growth Factor I (IGF I) plasma levels in children with Perthes' disease
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Growth and weight measures in children with Perthes' disease
Number of subjects: 59

Group type: COMPARATOR
Intervention: Insulin‐like Growth Factor I (IGF I) plasma levels in matched controls
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Degree of femoral head involvement according to Catterall (1971)
Number of subjects: 59
Study: 3859166

Group type: EXPERIMENTAL
Intervention: Diagnostic tool based on clinical criteria
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-eczematous controls
Number of subjects: 47
Study: 31395020

Group type: EXPERIMENTAL
Intervention: Facilitation intervention to increase uptake of evidence-based prevention of vascular disease
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Facilitation intervention
Number of subjects: 8
Study: 29099960

Group type: EXPERIMENTAL
Intervention: PNCA with a basal infusion
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PNCA without a basal infusion
Number of subjects: 81

Group type: COMPARATOR
Intervention: IV PRN opioids
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PNCA (both with and without basal infusion)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study: 27769879

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation practice (MMP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mindfulness meditation description (MMD)
Number of subjects: 36
Study: 24705678

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (3-month program)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 21985126

Group type: EXPERIMENTAL
Intervention: Fast-track care programme (n = 40)
Number of subjects: 78
Study: 25649195

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Valsartan (80 mg/day)
Number of subjects: 50
Study: 17964037

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078